2013 绎 Vol.15 No.2 阴 元元 元元 / 999078 5 doi: 10.11842/wst.2013.02.008 R283 A [1, 2] 2011-12-19 2012-04-11 元 MYRG208(Y1-L4)-ICMS11-WYT 元元 201
绎 1. [3] [4] 93.10% 13.68% [5] 78.87% 5.82% [6] [8] 2. [9] 72.2 nm GS 70~107 nm [10] [11] C 57.43% 3.48% 3 63.43% HepG 2 [12] 3. 茁 - 茁 - 颐 4 颐 1 [13] [14] [15] 8.27% 91.76% 5 1. Panax ginseng C. A. Mey. 202
2013 绎 Vol.15 No.2 Rg3 [16] Rh2 P- 17.6% 24.8% [17] [18] Rh2 SMEDDS SMEDDS 2h 56.8% Rh2 SMEDDS Rh2 [19] 2. Angelica sinensis (Oliv.) Diels [20] [21] 7 颐 3 45.5% 茁 - 98.6% 63.0% [22] - 茁 - [23] 4h 40% 4 h [24] 6000 [25] 3. Astragalus membranaceus (Fisch.) Bge. var. mongholi 原 cus (Bge.) Hsiao A stragalus mem 原 branaceus (Fisch.) Bge. [26, 27] [28] [29] 13.54 mg ml -1 24 h [30] EM 10 益 ~40 益 0.5~5 [31] [32] [33] - [34] - 茁 - 203
绎 [35] [36] 4. Codonopsis pilosula (Franch.) Nannf. [37~40] [41] [42] [43, 44] 2.534 mg 65% [45] [46] 5~10 min [47] 5. Ganoderma lucidum (Leyss.ex Fr.) Karst. NK [48] [49] Me [50] [51] [52] [53] 1 援 援 1999 4(5) 颐 281. 2 Liggins RT, Burt HM. Polyether -polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. Advanced drug delivery reviews, 2002, 54(2) 颐 191~202. 3 援 援 2011 17 颐 269. 4 援 援 2007 27(1) 颐 98~100. 5 援 援 2011 25(4) 颐 313~315. 6 援 援 2011 34(09) 颐 1429~1433. 7 援 援 2007 13(4) 颐 309~310. 8 援 204
2013 绎 Vol.15 No.2 援 2009 20(6) 颐 1506~1508. 9 援 援 2010 35(4) 颐 439~443. 10 Song X, L Zang, S Hu. Amplified immune response by ginseno 原 side-based nanoparticles (ginsomes). Vaccine, 2009, 27(17) 颐 2306~ 2311. 11 援 C 援 2007 7(6) 颐 413~416. 12 援 援 2006 24(6) 颐 1209~1230. 13 援 茁 - 援 2008 17(3) 颐 27~28. 14 援 援 2011 36(13) 颐 1751~1753. 15 援 援 2008 30(11) 颐 1043~1045. 16 援 Rg3 援 2011 11(2) 颐 180~182. 17 Xie HT, Wang GJ, Lv H, et al. Development of a HPLC-MS assay for ginsenoside Rh2, a new anti-tumor substance from natural prod 原 uct and its pharacokinetic study in dogs. Eur J Drug Metab Phar 原 macokinet, 2005, 30(1-2) 颐 63~67. 18 援 援 2009 30(5) 颐 410~413. 19 援 Rh2 援 2008 43(9) 颐 683~687. 20 援 援 2003 34(3) 颐 49~51. 21 援 援 2009 24(6) 颐 350~353. 22 援茁 - 援 2010 30(12) 颐 40~43. 23.., CN 102058639A, 2011-5-18. 24 援 RP-HPLC 援 2010 14(6) 颐 650~651. 25 援 援 2011 24(3) 颐 409~411. 26 援 援 2011 20(5) 颐 435~436. 27 援 援 2006 15(12) 颐 66~67. 28 援 援 2011(2) 颐 10~11. 29.., CN 102058654A, 2011-5-18. 30 援 援 2007 31(2) 颐 148~151. 31.., CN 101664432A, 2010-3-10. 32.., CN 101919900A,2010-12-22. 33 援 援 2011 42(3) 颐 470~473. 34.., CN 101507747B, 2010-12-1. 35 援 - 茁 - 援 2010 13(4) 颐 469~471. 36.., CN 101461837B, 2011-8-10. 37 援 援, 2008 11(2) 颐 33~39. 38 Byeon SE, Choi WS, Hong EK, et al. Inhibitory effect of saponin fraction from Codonopsis lanceolata on immune cell -mediated in 原 flammatory responses. Arch Pharm Res, 2009, 32(6) 颐 813~22. 39 Lee YG, Kim JY, Lee JY, et al. Regulatory effects of Codonopsis lanceolata on macrophage-mediated immune responses. JEthnophar 原 macol, 2007, 112(1) 颐 180~188. 40 Wang L, Xu ML, Hu JH, et al. Codonopsis lanceolata extract in 原 duces G0/G1 arrest and apoptosis in human colon tumor HT -29 cells involvement of ROS generation and polyamine depletion. Food Chem Toxicol, 49(1) 颐 149~154. 41.., CN 101744862A,2010-6-23. 42 援 援 2007 16 (10) 颐 1238~1240. 43 援 援 2010 41(3) 颐 231~233. 44 援 援 2010 10(5) 颐 515~516. 45 援 援 2004 13(2) 颐 104~105. 46.., CN 101816697A, 2010-9-1. 47 援 援 2010 16(8) 颐 95~96. 48 援 援 2005 21(5) 颐 36~38. 49.,. CN101601695A,2009-12-16. 50. Me., CN 101623502A, 2010-1-13. 205
绎 51 援 援 2007 8(1) 颐 42~44. 52 援 援 2005 28(9) 颐 827~828. 53 援 援 2004 27(10) 颐 778~779. Progress in Novel Drug Delivery System of Anti-tumor Chinese Medicine (Part Three) 要要 Fuzheng Guben Chinese Medicine Chen Ruie, Wang Shengpeng, Hu Yangyang, Chen Meiwan, Wang Yitao (State Key Laboratory of Quality Research in Chinese Medicine(University ofmacau), Institute of Chinese Medical Sciences, University of Macau, Macau 999078, China) Abstract: Fuzheng Guben (FZGB) Chinese medicine, or tonification Chinese medicine, is widely used to treat various malignant tumors through activating the spleen and replenishing qi, nourishing yin and enriching the blood, warming yang and reinforcing kidney. Modern Chinese medicine pharmacological researches have demon 鄄 strated that this kind of anti-tumor herbs is able to control immunosuppressive factors related to anti-tumor im 鄄 mune and response in host, which plays an important role in anti-cancer treatment. However, most of the active ingredients from FZGB Chinese medicine have shortcomings such as difficult absorption and low bioavailability. Hence, the treatment effect is not satisfied. During the past few decades, novel drug delivery system has become a hot research topic for the development of FZGB Chinese medicine. This paper mainly focused on the new drug delivery system of FZGB Chinese medicine, especially five commonly used medicine, namely Ginseng, Angelica sinensis, A stragalus mongholicus, Lucid ganoderma, and Codonopsis pilosula. This study is aimed to offer more references and evidences for the development of new formulations in anti- tumor Chinese medicine. Keywords: Anti-tumor Chinese medicine, novel drug delivery system, Fuzheng Guben Chinese medicine 206